Abstract
After cardiopulmonary bypass (CPB) approximately 20% of patients require platelets. In our safety-net hospital, the incidence of platelet transfusion is over 40%, perhaps attributable to our prevalent risk factors of renal dysfunction, CPB duration, and absence of tranexamic acid (TXA). We designed this retrospective observational study after surgeons decided against offering CPB in the presence of these risk factors. The Institutional Review Board (IRB) approved the protocol and waived informed consent. Our hypothesis was the number of platelet transfusions in the consecutive patients during the first ninety days of 2022 would be higher than those in 2023. Confounders included platelet counts and hemoglobin immediately before platelet transfusion. Secondary outcomes were postoperative day two creatinine and other components transfused. Preoperatively creatinine trended higher in 2022 at 1.5 vs 1.1, reaching significance postoperatively at 1.9 vs 1.1 (p=0.02). CPB decreased from 174 to 124 min (p=0.06). TXA use increased from 18 of 28 to 26 of 29 patients. Platelets during CPB increased (142 to 173, p=0.06). Hemoglobin nadirs rose (8 g/dL to 8.8, p=0.04). Platelet units transfused per patient tended to rise (0.7±1 vs 0.93±1.5); if exposed, patients tended to receive more units (2.1±1.3 vs 2.5±1.4) sooner. These data support a need for thromboelastograms with platelet mapping immediately post-CPB.